Meeting Coverage

Meeting Coverage

Rajat Bannerji: REGN1979 Active Across Non-Hodgkin Lymphoma Subtypes

The bispecific antibody REGN1979 demonstrated efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no observed dose-limiting toxicities. Rajat Bannerji, MD, PhD,...

Luciano Costa: CC-93269 Shows Clinical Activity in Previously Treated Myeloma

Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T...

Deepu Madduri: An Emerging CAR T-Cell Therapy for Myeloma

Deepu Madduri, MD, discusses findings from the CARTITUDE-1 trial, in which the new CAR T-cell therapy candidate led to a 100% response rate and...

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Combining MBG453 with hypomethylating agents was "extremely well tolerated," with no high-grade immune-related toxicities. Uma Borate, MD, discusses the safety and preliminary efficacy data.

David Steensma: Examining H3B-8800 for Myeloid Neoplasms

David Steensma, MD, discusses the results and unanswered questions raised by the first-in-human trial of the splicing modulator in patients with acute myeloid leukemia,...

Aaron Gerds: What Does the Future Hold for Pacritinib?

Aaron Gerds, MD, MS, shares results from the PAC203 trial, which enrolled patients with high-risk and heavily refractory myelofibrosis.

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients With AML

Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.

Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery in Patients With Leukemia

Iman Abou Dalle, MD, describes how blocking luteinizing hormone receptors with leuprolide can improve hematopoietic recovery in patients with leukemia who have undergone intensive...
Advertisement

Current Issue

January 2020 Annual Meeting Edition

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.